Climb Bio, Inc. financial data

Symbol
CLYM on Nasdaq
Location
Wellesley Hills, MA
Fiscal year end
31 December
Latest financial report
10-K - Q4 2025 - 05 Mar 2026

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1527% % -67%
Debt-to-equity 3.7% % 82%
Return On Equity -33% % 14%
Return On Assets -32% % 16%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 47,767,980 shares -29%
Common Stock, Shares, Outstanding 47,766,338 shares -29%
Entity Public Float $44,800,000 USD -77%
Common Stock, Value, Issued $5,000 USD -29%
Weighted Average Number of Shares Outstanding, Basic 67,812,145 shares 41%
Weighted Average Number of Shares Outstanding, Diluted 67,812,145 shares 41%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense $46,713,000 USD 226%
General and Administrative Expense $21,170,000 USD 32%
Operating Income (Loss) $67,883,000 USD 17%
Nonoperating Income (Expense) $2,004,000 USD -29%
Income Tax Expense (Benefit) $0 USD
Net Income (Loss) Attributable to Parent $59,851,000 USD 19%
Earnings Per Share, Basic -0.88 USD/shares 42%
Earnings Per Share, Diluted -0.88 USD/shares 42%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $35,685,000 USD -59%
Marketable Securities, Current $65,395,000 USD 2.7%
Cash, Cash Equivalents, and Short-term Investments $160,700,000 USD
Assets, Current $105,849,000 USD -32%
Property, Plant and Equipment, Net $288,000 USD 45%
Operating Lease, Right-of-Use Asset $505,000 USD 3.1%
Other Assets, Noncurrent $1,530,000 USD 9462%
Assets $167,744,000 USD -23%
Accounts Payable, Current $2,269,000 USD 222%
Employee-related Liabilities, Current $1,891,000 USD -5.3%
Accrued Liabilities, Current $6,104,000 USD 131%
Liabilities, Current $6,984,000 USD 42%
Operating Lease, Liability, Noncurrent $285,000 USD -24%
Other Liabilities, Noncurrent $0 USD -100%
Liabilities $7,269,000 USD 37%
Accumulated Other Comprehensive Income (Loss), Net of Tax $435,000 USD 1791%
Retained Earnings (Accumulated Deficit) $289,727,000 USD -26%
Stockholders' Equity Attributable to Parent $160,475,000 USD -24%
Liabilities and Equity $167,744,000 USD -23%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $15,434,000 USD -748%
Net Cash Provided by (Used in) Financing Activities $0 USD -100%
Net Cash Provided by (Used in) Investing Activities $42,751,000 USD -411%
Common Stock, Shares Authorized 250,000,000 shares 0%
Common Stock, Shares, Issued 47,766,338 shares -29%
Common Stock, Par or Stated Value Per Share 0.0001 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $58,209,000 USD -588%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $35,685,000 USD -59%
Deferred Tax Assets, Valuation Allowance $39,368,000 USD 38%
Deferred Tax Assets, Gross $39,459,000 USD 38%
Operating Lease, Liability $541,000 USD
Comprehensive Income (Loss), Net of Tax, Attributable to Parent $59,439,000 USD 20%
Lessee, Operating Lease, Liability, to be Paid $591,000 USD
Operating Lease, Liability, Current $256,000 USD 63%
Lessee, Operating Lease, Liability, to be Paid, Year Two $298,000 USD
Lessee, Operating Lease, Liability, to be Paid, Year One $293,000 USD
Operating Lease, Weighted Average Discount Rate, Percent 0.085 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount $50,000 USD
Deferred Tax Assets, Operating Loss Carryforwards $28,202,000 USD 24%
Deferred Tax Assets, Net of Valuation Allowance $91,000 USD -34%
Share-based Payment Arrangement, Expense $8,054,000 USD 45%